320 related articles for article (PubMed ID: 27460076)
1. The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins.
Li Z; Block MS; Vierkant RA; Fogarty ZC; Winham SJ; Visscher DW; Kalli KR; Wang C; Goode EL
Tumour Biol; 2016 Oct; 37(10):13279-13286. PubMed ID: 27460076
[TBL] [Abstract][Full Text] [Related]
2. Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers.
Kim KH; Jo MS; Suh DS; Yoon MS; Shin DH; Lee JH; Choi KU
World J Surg Oncol; 2012 Sep; 10():193. PubMed ID: 22985132
[TBL] [Abstract][Full Text] [Related]
3. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
4. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway.
Huang JM; Zhang GN; Shi Y; Zha X; Zhu Y; Wang MM; Lin Q; Wang W; Lu HY; Ma SQ; Cheng J; Deng BF
Sci Rep; 2014 Jan; 4():3840. PubMed ID: 24452475
[TBL] [Abstract][Full Text] [Related]
5. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
d'Adhemar CJ; Spillane CD; Gallagher MF; Bates M; Costello KM; Barry-O'Crowley J; Haley K; Kernan N; Murphy C; Smyth PC; O'Byrne K; Pennington S; Cooke AA; Ffrench B; Martin CM; O'Donnell D; Hennessy B; Stordal B; Finn S; McCann A; Gleeson N; D'Arcy T; Flood B; O'Neill LA; Sheils O; O'Toole S; O'Leary JJ
PLoS One; 2014; 9(6):e100816. PubMed ID: 24977712
[TBL] [Abstract][Full Text] [Related]
6. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
7. Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-κB signaling in vitro.
Liu H; Zhang G; Huang J; Ma S; Mi K; Cheng J; Zhu Y; Zha X; Huang W
J Transl Med; 2016 Apr; 14(1):104. PubMed ID: 27118139
[TBL] [Abstract][Full Text] [Related]
8. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.
Block MS; Vierkant RA; Rambau PF; Winham SJ; Wagner P; Traficante N; Tołoczko A; Tiezzi DG; Taran FA; Sinn P; Sieh W; Sharma R; Rothstein JH; Ramón Y Cajal T; Paz-Ares L; Oszurek O; Orsulic S; Ness RB; Nelson G; Modugno F; Menkiszak J; McGuire V; McCauley BM; Mack M; Lubiński J; Longacre TA; Li Z; Lester J; Kennedy CJ; Kalli KR; Jung AY; Johnatty SE; Jimenez-Linan M; Jensen A; Intermaggio MP; Hung J; Herpel E; Hernandez BY; Hartkopf AD; Harnett PR; Ghatage P; García-Bueno JM; Gao B; Fereday S; Eilber U; Edwards RP; de Sousa CB; de Andrade JM; Chudecka-Głaz A; Chenevix-Trench G; Cazorla A; Brucker SY; ; Alsop J; Whittemore AS; Steed H; Staebler A; Moysich KB; Menon U; Koziak JM; Kommoss S; Kjaer SK; Kelemen LE; Karlan BY; Huntsman DG; Høgdall E; Gronwald J; Goodman MT; Gilks B; García MJ; Fasching PA; de Fazio A; Deen S; Chang-Claude J; Candido Dos Reis FJ; Campbell IG; Brenton JD; Bowtell DD; Benítez J; Pharoah PDP; Köbel M; Ramus SJ; Goode EL
Mayo Clin Proc; 2018 Mar; 93(3):307-320. PubMed ID: 29502561
[TBL] [Abstract][Full Text] [Related]
9. Melatonin attenuates the TLR4-mediated inflammatory response through MyD88- and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer.
Chuffa LG; Fioruci-Fontanelli BA; Mendes LO; Ferreira Seiva FR; Martinez M; Fávaro WJ; Domeniconi RF; Pinheiro PF; Delazari Dos Santos L; Martinez FE
BMC Cancer; 2015 Feb; 15():34. PubMed ID: 25655081
[TBL] [Abstract][Full Text] [Related]
10. Loss of BMI-1 dampens migration and EMT of colorectal cancer in inflammatory microenvironment through TLR4/MD-2/MyD88-mediated NF-κB signaling.
Ye K; Chen QW; Sun YF; Lin JA; Xu JH
J Cell Biochem; 2018 Feb; 119(2):1922-1930. PubMed ID: 28815730
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells.
Zhu Y; Huang JM; Zhang GN; Zha X; Deng BF
J Transl Med; 2012 Apr; 10():77. PubMed ID: 22533866
[TBL] [Abstract][Full Text] [Related]
12. TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence.
Chefetz I; Alvero AB; Holmberg JC; Lebowitz N; Craveiro V; Yang-Hartwich Y; Yin G; Squillace L; Gurrea Soteras M; Aldo P; Mor G
Cell Cycle; 2013 Feb; 12(3):511-21. PubMed ID: 23324344
[TBL] [Abstract][Full Text] [Related]
13. Expression and cellular distribution of TLR4, MyD88, and NF-κB in diabetic renal tubulointerstitial fibrosis, in vitro and in vivo.
Liu P; Li F; Qiu M; He L
Diabetes Res Clin Pract; 2014 Aug; 105(2):206-16. PubMed ID: 24894085
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L
Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797
[TBL] [Abstract][Full Text] [Related]
15. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
16. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.
Szajnik M; Szczepanski MJ; Czystowska M; Elishaev E; Mandapathil M; Nowak-Markwitz E; Spaczynski M; Whiteside TL
Oncogene; 2009 Dec; 28(49):4353-63. PubMed ID: 19826413
[TBL] [Abstract][Full Text] [Related]
17. Association between the HMGB1/TLR4 signaling pathway and the clinicopathological features of ovarian cancer.
Jiang C; Qu X; Ke H; Gong W; Chen R; Yang W; Cheng Z
Mol Med Rep; 2018 Sep; 18(3):3093-3098. PubMed ID: 30015957
[TBL] [Abstract][Full Text] [Related]
18. P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.
de Almeida Chuffa LG; de Moura Ferreira G; Lupi LA; da Silva Nunes I; Fávaro WJ
J Ovarian Res; 2018 Jan; 11(1):8. PubMed ID: 29343281
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer.
Paek J; Lee M; Nam EJ; Kim SW; Kim YT
Arch Gynecol Obstet; 2016 Mar; 293(3):645-50. PubMed ID: 26305032
[TBL] [Abstract][Full Text] [Related]
20. Effects of the TLR4/Myd88/NF-κB Signaling Pathway on NLRP3 Inflammasome in Coronary Microembolization-Induced Myocardial Injury.
Su Q; Li L; Sun Y; Yang H; Ye Z; Zhao J
Cell Physiol Biochem; 2018; 47(4):1497-1508. PubMed ID: 29940584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
